Wealthfront Advisers LLC Has $2.74 Million Stock Holdings in Biogen Inc. $BIIB

Wealthfront Advisers LLC raised its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 37.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,551 shares of the biotechnology company’s stock after purchasing an additional 4,227 shares during the period. Wealthfront Advisers LLC’s holdings in Biogen were worth $2,737,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Advisory Services Network LLC boosted its position in shares of Biogen by 3.9% in the third quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock valued at $251,000 after acquiring an additional 68 shares during the period. CVA Family Office LLC boosted its position in shares of Biogen by 18.1% in the third quarter. CVA Family Office LLC now owns 464 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 71 shares during the period. Davis Investment Partners LLC boosted its position in shares of Biogen by 1.7% in the fourth quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock valued at $778,000 after acquiring an additional 71 shares during the period. Optas LLC boosted its position in shares of Biogen by 4.5% in the fourth quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock valued at $300,000 after acquiring an additional 73 shares during the period. Finally, TD Private Client Wealth LLC boosted its position in shares of Biogen by 22.5% in the third quarter. TD Private Client Wealth LLC now owns 414 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 76 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BIIB. Stifel Nicolaus increased their price objective on Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a research report on Friday, February 6th. JPMorgan Chase & Co. increased their price objective on Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a research report on Thursday, April 23rd. Barclays began coverage on Biogen in a research report on Thursday, February 19th. They issued an “equal weight” rating and a $185.00 price objective for the company. Wall Street Zen raised Biogen from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Rothschild & Co Redburn increased their price objective on Biogen from $180.00 to $190.00 in a research report on Thursday. Thirteen investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Biogen currently has a consensus rating of “Hold” and an average price target of $214.23.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q1 beat driven by growth from newer drugs (Leqembi, Skyclarys) and upbeat revenue/profit metrics that underpin optimism about Biogen’s growth portfolio. Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
• Positive Sentiment: RBC raised its price target to $222 and maintained an Outperform rating, signaling strong analyst conviction and upside potential for BIIB. RBC raises PT to $222
• Positive Sentiment: H.C. Wainwright reiterated a Buy and lifted its PT to $237, citing reduced risk on BIIB080 (Alzheimer’s) — a bullish signal for upside from pipeline progress. H.C. Wainwright reiterates Buy, PT $237
• Positive Sentiment: TD Cowen initiated / affirmed a Buy with a $215 price target, citing strong Q1, pipeline progress and the Apellis deal as supportive factors. TD Cowen Buy, PT $215
• Positive Sentiment: Rothschild & Co Redburn nudged its PT up to $190 (small upside), reflecting modestly improved near-term views. Rothschild raises PT to $190
• Neutral Sentiment: BMO kept a Market Perform/Hold rating with an unchanged $196 target, signaling that some analysts see constrained near-term growth despite the beat. BMO maintains Hold, PT $196
• Neutral Sentiment: Several analyst notes and commentary highlight mixed takeaways: firms generally raised forecasts after the Q1 beat but some also trimmed FY2026 EPS expectations, producing varied buy/hold calls. Analysts boost forecasts after Q1
• Negative Sentiment: Biogen disclosed the Apellis transaction will create a ~$120M–$130M other‑income headwind in 2026 (non‑GAAP EPS accretion expected in 2027), creating a near‑term earnings drag that pressured sentiment. Apellis deal impact
• Negative Sentiment: Sanford C. Bernstein trimmed its PT slightly from $201 to $200 — a modest negative signal that may contribute to profit-taking amid mixed analyst reactions. Bernstein trims PT to $200

Insider Buying and Selling

In related news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the transaction, the insider directly owned 8,043 shares of the company’s stock, valued at $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.18% of the stock is currently owned by company insiders.

Biogen Stock Down 1.2%

Shares of BIIB stock opened at $187.06 on Friday. The stock has a market cap of $27.45 billion, a P/E ratio of 20.07, a price-to-earnings-growth ratio of 1.55 and a beta of 0.16. Biogen Inc. has a one year low of $115.25 and a one year high of $202.41. The stock has a fifty day moving average price of $184.52 and a 200 day moving average price of $176.06. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.03.

Biogen (NASDAQ:BIIB) last issued its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, topping the consensus estimate of $2.95 by $0.62. The firm had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.Biogen’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period last year, the business earned $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Analysts predict that Biogen Inc. will post 15.26 earnings per share for the current year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.